JARDIANCE Drug Patent Profile
✉ Email this page to a colleague
When do Jardiance patents expire, and what generic alternatives are available?
Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and eighty patent family members in forty-five countries.
The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.
DrugPatentWatch® Generic Entry Outlook for Jardiance
Jardiance was eligible for patent challenges on August 1, 2018.
Annual sales in 2021 were $7.6bn, indicating a strong incentive for generic entry.
There have been fifteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are fourteen tentative approvals for the generic drug (empagliflozin), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JARDIANCE?
- What are the global sales for JARDIANCE?
- What is Average Wholesale Price for JARDIANCE?
Summary for JARDIANCE
| International Patents: | 280 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 75 |
| Patent Applications: | 686 |
| Drug Prices: | Drug price information for JARDIANCE |
| Drug Sales Revenues: | Drug sales revenues for JARDIANCE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JARDIANCE |
| What excipients (inactive ingredients) are in JARDIANCE? | JARDIANCE excipients list |
| DailyMed Link: | JARDIANCE at DailyMed |
Recent Clinical Trials for JARDIANCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Medical Center Groningen | Phase 4 |
| Rigshospitalet, Denmark | Phase 4 |
| Novo Nordisk A/S | Phase 3 |
Pharmacology for JARDIANCE
| Drug Class | Sodium-Glucose Cotransporter 2 Inhibitor |
| Mechanism of Action | Sodium-Glucose Transporter 2 Inhibitors |
Paragraph IV (Patent) Challenges for JARDIANCE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| JARDIANCE | Tablets | empagliflozin | 10 mg and 25 mg | 204629 | 14 | 2018-08-01 |
US Patents and Regulatory Information for JARDIANCE
JARDIANCE is protected by twelve US patents and six FDA Regulatory Exclusivities.
Patents protecting JARDIANCE
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION IN PATIENTS WITH HEART FAILURE BY ADMINISTRATION OF EMPAGLIFLOZIN
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND
Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting JARDIANCE
REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
Exclusivity Expiration: ⤷ Sign Up
USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF SUSTAINED DECLINE IN EGFR, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
Exclusivity Expiration: ⤷ Sign Up
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
LABELING REVISIONS RELATED TO CLINICAL STUDIES
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | JARDIANCE | empagliflozin | TABLET;ORAL | 204629-002 | Aug 1, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | JARDIANCE | empagliflozin | TABLET;ORAL | 204629-002 | Aug 1, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Boehringer Ingelheim | JARDIANCE | empagliflozin | TABLET;ORAL | 204629-001 | Aug 1, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for JARDIANCE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Jardiance | empagliflozin | EMEA/H/C/002677 Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease. |
Authorised | no | no | no | 2014-05-22 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for JARDIANCE
When does loss-of-exclusivity occur for JARDIANCE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7970
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO
Estimated Expiration: ⤷ Sign Up
Patent: 7657
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 08288407
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0815331
Patent: composição farmacêutica compreendendo um derivado de benzeno glucopiranosila substituída
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 96558
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT UN DERIVE DE BENZENE A SUBSTITUTION GLUCOPYRANOSYLE (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 08002427
Patent: Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
Estimated Expiration: ⤷ Sign Up
China
Patent: 1784270
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Patent: 4288166
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Patent: 4353077
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 51239
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO JUNTO CON UN INHIBIDOR DE DPP IV
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0170022
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 18308
Estimated Expiration: ⤷ Sign Up
Patent: 17017
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 87879
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 109977
Patent: Composición farmacéutica que comprende un derivado de benceno sustituido con glucopiranosilo.
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8608
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ГЛЮКОПИРАНОЗИЛЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ БЕНЗОЛА И ИНГИБИТОР DPP IV (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE AND DPP IV INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 1000321
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ГЛЮКОПИРАНОЗИЛЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ БЕНЗОЛА
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 87879
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT UN DÉRIVÉ DE BENZÈNE À SUBSTITUTION GLUCOPYRANOSYLE (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Patent: 98152
Patent: Composition pharmaceutique comprenant un dérivé de benzène substitué de glucopyranosyl (Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative)
Estimated Expiration: ⤷ Sign Up
Patent: 06156
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT UN DÉRIVÉ DE BENZÈNE SUBSTITUÉ PAR GLUCOPYRANOSYLE (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Patent: 39577
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT UN DÉRIVÉ DE BENZÈNE SUBSTITUÉ PAR GLUCOPYRANOSYLE (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 01721
Patent: 包含吡喃葡萄糖基-取代的苯衍生物的藥物組合物 (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Patent: 03351
Patent: 包含吡喃葡萄糖基-取代的苯衍生物的藥物組合物 (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 30158
Estimated Expiration: ⤷ Sign Up
Patent: 700020
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2886
Patent: תכשיר רוקחות המכיל תולדת בנזן המותמרת בגלוקופיראנוזיל, באופן בריירתי המכילה בנוסף מעכב iv dpp ושימוש בו לייצור תרופה המונעת, מאיטה, מעכבת או מטפלת באי סדר מטבולי (Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative, optionally further comprising a dpp iv inhibitor and use thereof in the manufacture of a medicament for preventing, slowing, delaying or treating a metabolic disorder)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 95914
Estimated Expiration: ⤷ Sign Up
Patent: 10535850
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 187879
Estimated Expiration: ⤷ Sign Up
Patent: 2017014
Estimated Expiration: ⤷ Sign Up
Patent: 87879
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 2037
Patent: PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10001696
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO. (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTE D BENZENE DERIVATIVE.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 573
Patent: FARMACEUTSKA KOMPOZICIJA KOJA SADRŽI GLUKOPIRANOZILOM SUPSTITUISANI DERIVAT BENZENA (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 612
Patent: COMPOSITION PHARMACEUTIQUE CONTENANT UN DERIVE DE BENZENE SUBSTITUE PAR GLUCOPYRANOSYLE
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 0872
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3242
Patent: PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 17020
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 090938
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 87879
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 87879
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 205
Patent: FARMACEUTSKA KOMPOZICIJA KOJA SADRŽI GLUKOPIRANOZILOM SUPSTITUISANI DERIVAT BENZENA (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 87879
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0909105
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1491554
Estimated Expiration: ⤷ Sign Up
Patent: 100049595
Patent: PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 02748
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 72325
Estimated Expiration: ⤷ Sign Up
Patent: 0914030
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Patent: 1436798
Patent: Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 10000073
Patent: COMPOSITON PHARMACEUTIQUE CONTENANT UN DERIVE DE BENZENE SUBSTITUE PAR GLUCOPYRANOSYLE
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 0384
Patent: ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ ГЛЮКОПІРАНОЗИЛЗАМІЩЕНУ ПОХІДНУ БЕНЗОЛУ ТА ІНГІБІТОР DPP IV (PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 296
Patent: COMPOSICION FARMACÉUTICA QUE COMPRENDE UN DERIVADO DE BENCENO SUSTITUIDO CON GLUCOPIRANOSILO
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering JARDIANCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 105263485 | Therapeutic uses of empagliflozin | ⤷ Sign Up |
| Israel | 287516 | שימושים רפואיים באמפאגליפלוזין (Therapeutic uses of empagliflozin) | ⤷ Sign Up |
| Peru | 20060120 | DERIVADOS DE BENCENO SUSTITUIDOS POR GLUCOPIRANOSILO, MEDICAMENTOS QUE CONTIENEN ESOS COMPUESTOS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JARDIANCE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2187879 | SPC/GB17/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 1-CHLORO-4-(SS-D-GLUCOPYRANOS-1-YL)-2-(4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL)-BENZENE (I.E. EMPAGLIFLOZIN) IN COMBINATION WITH 1-((4 METHYL-QUINAZOLIN-2-YL)METHYL)-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-(R)-AMINO-PIPERIDIN-1-YL)-XANTHINE (I.E. LINAGLIPTIN) OR A P; REGISTERED: UK PLGB 14598/0191 (GB) 20161115; UK EU/1/16/1146/014(NI) 20161115; UK EU/1/16/1146/015(NI) 20161115; UK EU/1/16/1146/016(NI) 20161115; UK EU/1/16/1146/017(NI) 20161115; UK EU/1/16/1146/018(NI) 20161115; UK EU/1/16/1146/007(NI) 20161115; UK EU/1/16/1146/001(NI) 20161115; UK EU/1/16/1146/013(NI) 20161115; UK EU/1/16/1146/002(NI) 20161115; UK EU/1/16/1146/003(NI) 20161115; UK EU/1/16/1146/004(NI) 20161115; UK... |
| 2187879 | PA2017014 | Lithuania | ⤷ Sign Up | PRODUCT NAME: EMPAGLIFLOZINO IR LINAGLIPTINO DERINYS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1146/001 - EU/1/16/1146/018 20161111 |
| 2187879 | 17C1016 | France | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D'EMPAGLIFLOZINE ET DE LINAGLIPTINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/16/1146 20161115 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
